Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HANK immunotherapy for tongue cancer metastases
NCT03008330Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HANK cells in tongue cancer, sponsored by Fuda Cancer Hospital. Started Dec 2016; status: completed.
02
Drugs
HANK cells
03
Conditions
tongue cancer
Beyond the preview
Go deeper on NCT03008330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008330.